Setting Precedents for Rare Disease Therapies

Pharmaceutical Executive: What precedent do you think Papzimeos sets for future therapies in rare diseases?
Helen Sabzevari: So this led to papzimeos being the standard of care, the first and only FDA approved drug for RRP, and the label is for all adult RRP patients, which is a broad label. And I think this is very important, because now any of the adults diagnosed with the RRP, they are eligible to receive the papzimeos starting and the reason that this is important for this patient population, studies coming out of John Hopkins have shown that these patients, by the time they get to the fifth surgery, they already have irreversible damage to their vocal cords and to their trachea. So definitely, it becomes not only important for patients that they have severe cases, but also even the patients that immediately start being diagnosed with the RRP, because, for sure, the physicians, they do not want these patients to get to that level of damage that they cannot reverse it back. And I think that's the strength of this drug, and also the importance of having a label that now all adult or RP patients can be treated with this.